Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chimeric RNA/DNA oligonucleotide-based gene therapy.

Li-Wen Lai1, Yeong-Hau H Lien

  • 1Department of Medicine, Sections of Endocrinology and Nephrology, University of Arizona Health Sciences Center, Tucson, Arizona 85724, USA.

Kidney International
|February 14, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is it Time to Set a 25% Decrease in eGFR as Criteria for Community-Acquired Acute Kidney Injury in Primary Care Clinics?

The American journal of medicine·2024
Same author

Stomatitis and Bone Marrow Suppression Followed by Leukoerythroblastosis in a Patient on Long-Term Low-Dose Methotrexate Therapy.

The American journal of medicine·2022
Same author

Digenic Inheritance of a FOXC2 Mutation and Two PIEZO1 Mutations Underlies Congenital Lymphedema in a Multigeneration Family.

The American journal of medicine·2021
Same author

Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease.

ACS pharmacology & translational science·2021
Same author

Rare monosomy 7 and deletion 7p at diagnosis of chronic myeloid leukemia in accelerated phase.

Cancer genetics·2021
Same author

Exome sequencing in patients with microphthalmia, anophthalmia, and coloboma (MAC) from a consanguineous population.

Clinical genetics·2020

Chimeric RNA/DNA oligonucleotides show promise for gene therapy, correcting genetic mutations with significant efficiency. This approach offers a potential pathway for long-term gene expression and regulation in genetic disease models.

Area of Science:

  • Molecular Biology
  • Genetics
  • Biotechnology

Background:

  • Chimeric RNA/DNA oligonucleotides are an emerging gene therapy strategy.
  • They have demonstrated site-specific correction of point mutations in genetic disease models.

Purpose of the Study:

  • To review recent studies on chimeric RNA/DNA oligonucleotide-based gene therapy.
  • To assess the efficacy and potential of this approach for genetic diseases.

Main Methods:

  • Reviewed six studies using chimeric RNA/DNA oligonucleotides in genetic disease models.
  • Oligonucleotides targeted genomic DNA flanking mutation sites.
  • Assessed genotypic and phenotypic corrections using various molecular and functional assays.

Main Results:

Related Experiment Videos

  • Gene correction frequencies ranged from less than 1% to over 40%.
  • Observed conversion rates were significantly higher than homologous recombination.
  • Phenotypic changes persisted for over a year in some cases.

Conclusions:

  • Chimeric RNA/DNA oligonucleotide therapy holds potential as a therapeutic modality for genetic diseases.
  • This method may provide permanent expression and normal gene regulation.
  • Further research into mechanisms is needed to enhance efficacy and safety.